Merck, Keytruda and Eisai

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way.
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Merck sees 2025 launch for simpler version of cancer drug Keytruda
Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year.
Merck and Eisai report mixed results in Phase 3 cancer trial
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, which evaluated the efficacy of the combination therapy KEYTRUDA and LENVIMA for patients with advanced gastroesophageal adenocarcinoma.
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese pharma giant’s tyrosine kinase inhibitor Lenvima for a certain type of cancer in the gastrointestinal tract.
Merck & Co. Inc. stock underperforms Friday when compared to competitors
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?
We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...
FiercePharma1d
RFK Jr.'s referral fees in litigation over Merck's Gardasil raise conflict-of-interest questions: reports
Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...
Yahoo Finance1d
Merck & Co., Inc. (MRK)
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...
Why Is Merck & Co., Inc. (MRK) Among the Best Large-Cap Value Stocks to Buy in 2025?
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
GlobalData on MSN12h
Merck and Opentrons to automate assay kits on custom workstation
Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...
FierceBiotech1d
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...